Kenya is set to be one of the first nine African countries to receive lenacapavir, a long-acting HIV prevention drug, through a recent deal with Global Fund.

• Lenacapavir will be available in Kenya by January 2026, aiming to aid in the goal of eliminating HIV/AIDS by 2030.
• The Global Fund has partnered with Gilead Sciences to supply this drug to over 120 low- and middle-income countries.
• This drug, taken twice a year, represents a significant improvement in HIV prevention options, targeting a community of 1.378 million Kenyans currently living with HIV.